ActivePhase 3ACTRN12605000142639

Good Prognosis Germ Cell Trial

Randomised, Phase III, trial for good prognosis germ cell tumours comparing two different regimes of cisplatin, etoposide and bleomycin.

Sponsor

Australian and New Zealand Germ Cell Trials Group at NHMRC Clinical Trials Centre

Enrollment

260 participants

Start Date

Jan 5, 1994

Study Type

Interventional

Conditions

Histologically confirmed germ cell tumour (seminoma or non-seminoma) with measurable disease or raised concentrations of tumor markers in serum.

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This clinical trial involves a Good Prognosis Germ Cell Trial. You may be eligible if you are with germ cell tumour. Participation may involve medical assessments, follow-up visits, and possibly receiving a study treatment or placebo.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A multicentre randomised trial to compare two standard chemotherapy regimens for men with good prognosis germ cell tumours. Treatment arm A and B both consisted of cisplatin, etoposide and bleomycin,

A multicentre randomised trial to compare two standard chemotherapy regimens for men with good prognosis germ cell tumours. Treatment arm A and B both consisted of cisplatin, etoposide and bleomycin, but was different in doses and the number of cycles. The trial was stopped when the second planned interim analysis met predefined stopping rules. Overall survival was substantially better with treatment arm A.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000142639